Yusuke Chihara Selected Research

Drug Therapy (Chemotherapy)

1/2024	Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49%: a multicenter retrospective study.
1/2024	Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50.
11/2023	Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status.
10/2023	First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand 1 Expression: A Real-World Multicenter Retrospective Study.
4/2023	Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etoposide Chemotherapy: A Prospective Observational Study.
1/2023	Prospective Observational Study Evaluating the Prognostic Value of the G8 Screening Tool for Extensive-Stage Small Cell Lung Cancer Patients Who Received Programmed Death-Ligand 1 Inhibitor plus Platinum-Etoposide Chemotherapy.
1/2023	Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
1/2023	Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
2/2022	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
11/2021	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yusuke Chihara Research Topics

Disease

47	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 01/2018
26	Neoplasms (Cancer) 03/2024 - 12/2018
10	Lung Neoplasms (Lung Cancer) 04/2024 - 01/2019
4	COVID-19 04/2023 - 01/2022
3	Disease Progression 01/2024 - 10/2018
3	Adenocarcinoma of Lung 04/2023 - 01/2020
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023 - 11/2019
2	Pneumonia (Pneumonitis) 04/2024 - 01/2022
2	Neoplasm Metastasis (Metastasis) 11/2023 - 03/2019
2	Cachexia 09/2023 - 01/2021
2	Carcinoma (Carcinomatosis) 01/2023 - 01/2020
2	Pericardial Effusion 12/2022 - 01/2019
1	Inflammation (Inflammations) 09/2023
1	Bacteremia 04/2023
1	Vasculitis (Vasculitides) 01/2023
1	Brain Neoplasms (Brain Tumor) 01/2023
1	Weight Loss (Weight Reduction) 01/2022
1	Severe Acute Respiratory Syndrome 01/2022
1	Prostatic Neoplasms (Prostate Cancer) 08/2021
1	Body Weight (Weight, Body) 01/2020
1	Sarcopenia 04/2019
1	Starvation 03/2019
1	Acidosis 03/2019
1	Hypoxia (Hypoxemia) 03/2019
1	Constipation 01/2019

Drug/Important Bio-Agent (IBA)

18	ErbB Receptors (EGF Receptor)IBA 04/2024 - 01/2018
16	Tyrosine Kinase InhibitorsIBA 04/2024 - 01/2018
16	Immune Checkpoint InhibitorsIBA 01/2024 - 01/2019
13	osimertinibIBA 04/2024 - 01/2019
8	Docetaxel (Taxotere)FDA Link 03/2024 - 01/2019
8	B7-H1 AntigenIBA 10/2023 - 08/2019
6	PlatinumIBA 01/2024 - 01/2018
5	RamucirumabIBA 03/2024 - 08/2019
5	pembrolizumabIBA 11/2023 - 08/2019
3	AntibodiesIBA 03/2024 - 11/2019
3	LigandsIBA 11/2023 - 01/2022
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2019 - 01/2019
2	durvalumabIBA 09/2023 - 01/2020
2	Etoposide (VP 16)FDA LinkGeneric 04/2023 - 01/2023
2	RNA (Ribonucleic Acid)IBA 02/2023 - 01/2022
2	Bevacizumab (Avastin)FDA Link 12/2022 - 01/2019
2	amrubicinIBA 09/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 12/2018
2	NivolumabIBA 05/2020 - 08/2019
2	AfatinibIBA 02/2019 - 10/2018
2	Cytotoxins (Cytolysins)IBA 01/2019 - 01/2019
1	serum P-component (CIt)IBA 10/2023
1	C-Reactive ProteinIBA 09/2023
1	Epidermal Growth Factor (EGF)IBA 06/2023
1	Anti-Infective Agents (Microbicides)IBA 04/2023
1	SteroidsIBA 04/2023
1	Phosphotransferases (Kinase)IBA 02/2023
1	Proteins (Proteins, Gene)FDA Link 02/2023
1	Proton Pump InhibitorsIBA 01/2023
1	pegfilgrastim (Neulasta)FDA Link 01/2023
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2023
1	EnzymesIBA 09/2022
1	DNA (Deoxyribonucleic Acid)IBA 09/2022
1	Topoisomerase II InhibitorsIBA 09/2022
1	mRNA VaccinesIBA 01/2022
1	4- (3'- (2'- chlorophenyl)- 2'- propen- 1'- ylidene)- 1- phenyl- 3,5- pyrazolidinedioneIBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Interferon Type IIBA 01/2022
1	Dihydrotachysterol (AT 10)IBA 01/2022
1	alectinibIBA 11/2021
1	Anaplastic Lymphoma KinaseIBA 11/2021
1	Prednisolone (Predate)FDA LinkGeneric 08/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	Antinuclear AntibodiesIBA 11/2020
1	atezolizumabIBA 10/2020
1	Histone Deacetylase InhibitorsIBA 01/2020
1	Mirtazapine (Rexer)FDA LinkGeneric 01/2020
1	Antineoplastic Agents (Antineoplastics)IBA 01/2020
1	Phosphopyruvate Hydratase (Enolase)IBA 11/2019
1	dacomitinibIBA 08/2019
1	Therapeutic UsesIBA 08/2019
1	Indicators and Reagents (Reagents)IBA 04/2019
1	Glucose (Dextrose)FDA LinkGeneric 03/2019
1	Angiogenesis InhibitorsIBA 03/2019
1	Nicotine FDA Link 02/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2019
1	LaxativesIBA 01/2019
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2019
1	Pemetrexed (MTA)FDA Link 01/2019
1	Gefitinib (Iressa)FDA Link 10/2018

Therapy/Procedure

28	Therapeutics 04/2024 - 01/2019
17	Drug Therapy (Chemotherapy) 01/2024 - 01/2018
9	Immunotherapy 10/2023 - 01/2019
2	Chemoradiotherapy 09/2023 - 01/2020
1	Induction Chemotherapy 09/2022
1	Combination Drug Therapy (Combination Chemotherapy) 01/2021
1	Aftercare (After-Treatment) 06/2020
1	Radiotherapy 01/2020